These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
24. New strategies in managing and preventing atherosclerosis: focus on HDL. Price MJ; Shah PK Rev Cardiovasc Med; 2002; 3(3):129-37. PubMed ID: 12439437 [TBL] [Abstract][Full Text] [Related]
25. Regulatory considerations in the development of high-density lipoprotein therapies. Orloff DG Am J Cardiol; 2007 Dec; 100(11 A):n10-4. PubMed ID: 18047846 [TBL] [Abstract][Full Text] [Related]
26. The importance of recognizing and treating low levels of high-density lipoprotein cholesterol: a new era in atherosclerosis management. Cardenas GA; Lavie CJ; Cardenas V; Milani RV; McCullough PA Rev Cardiovasc Med; 2008; 9(4):239-58. PubMed ID: 19122582 [TBL] [Abstract][Full Text] [Related]
27. High-density lipoprotein as a therapeutic target: clinical evidence and treatment strategies. Toth PP Am J Cardiol; 2005 Nov; 96(9A):50K-58K; discussion 34K-35K. PubMed ID: 16291015 [TBL] [Abstract][Full Text] [Related]
29. Targeting cholesteryl ester transfer protein for the prevention and management of cardiovascular disease. Barter PJ; Kastelein JJ J Am Coll Cardiol; 2006 Feb; 47(3):492-9. PubMed ID: 16458126 [TBL] [Abstract][Full Text] [Related]
30. Cardiovascular diseases in patients with high levels of plasma high density lipoprotein: association with increased plasma oxidative state. Shimoni N; Kaplan M; Keidar S Isr Med Assoc J; 2003 Oct; 5(10):702-5. PubMed ID: 14719463 [TBL] [Abstract][Full Text] [Related]
31. High-density lipoproteins, platelets and the pathogenesis of atherosclerosis. Nofer JR; Brodde MF; Kehrel BE Clin Exp Pharmacol Physiol; 2010 Jul; 37(7):726-35. PubMed ID: 20337657 [TBL] [Abstract][Full Text] [Related]
32. What does the future hold for niacin as a treatment for hyperlipidaemia and cardiovascular disease? Ahmed MH J Cardiovasc Med (Hagerstown); 2010 Nov; 11(11):858-60. PubMed ID: 20686417 [TBL] [Abstract][Full Text] [Related]
33. Demystifying good high-density lipoprotein from dysfunctional high-density lipoprotein. Drown DJ Prog Cardiovasc Nurs; 2008; 23(4):198-9. PubMed ID: 19067988 [No Abstract] [Full Text] [Related]
34. Niacin and fibrates in atherogenic dyslipidemia: pharmacotherapy to reduce cardiovascular risk. Chapman MJ; Redfern JS; McGovern ME; Giral P Pharmacol Ther; 2010 Jun; 126(3):314-45. PubMed ID: 20153365 [TBL] [Abstract][Full Text] [Related]
36. HDL slowing down endothelial progenitor cells senescence: a novel anti-atherogenic property of HDL. Pu DR; Liu L Med Hypotheses; 2008; 70(2):338-42. PubMed ID: 17640824 [TBL] [Abstract][Full Text] [Related]
37. From pathophysiology to targeted therapy for atherothrombosis: a role for the combination of statin and aspirin in secondary prevention. Chapman MJ Pharmacol Ther; 2007 Jan; 113(1):184-96. PubMed ID: 17070923 [TBL] [Abstract][Full Text] [Related]
38. [Cholesterol bound to high density lipoproteins: critical review of the methods of analysis and personal data]. Orso Giacone G Ann Osp Maria Vittoria Torino; 1982; 24(7-12):286-306. PubMed ID: 7137764 [TBL] [Abstract][Full Text] [Related]
39. Frontiers in research series: Physiological and pathological functions of high-density lipoprotein. Introduction. Sviridov D Clin Exp Pharmacol Physiol; 2010 Jul; 37(7):700-2. PubMed ID: 20374253 [No Abstract] [Full Text] [Related]
40. Targeting the anti-inflammatory effects of high-density lipoprotein. Ansell BJ Am J Cardiol; 2007 Dec; 100(11 A):n3-9. PubMed ID: 18047850 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]